IMNN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IMNN is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to invest. The stock has no strong proprietary buy signal today, the trend is still bearish, and the latest quarter shows weak financial performance with continued losses. The only clear positive is a fresh analyst Buy rating with a $10 target, but that alone is not enough to override the current technical and fundamental weakness. My direct view: hold off for now rather than buy immediately.
The current pre-market price is 2.83, which is below the pivot level of 2.914 and only slightly above support at 2.704. Momentum is weak: MACD histogram is negative, though slightly contracting, and RSI_6 at 44.612 is neutral with no strong upside momentum. The moving averages are bearish, with SMA_200 > SMA_20 > SMA_5, which confirms a downtrend. Near-term pattern data suggests a possible short-term bounce, but the overall setup is not a clean long-term entry.
["Maxim initiated coverage on 2026-04-17 with a Buy rating and a $10 price target.", "Pattern-based trend data suggests a possible upside move over the next day, week, and month."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "No AI Stock Picker signal today.", "No SwingMax signal recently.", "Hedge funds are neutral with no significant recent trading trends.", "Insiders are neutral with no significant recent trading trends.", "Revenue remains at 0 in the latest quarter.", "The company posted a net loss of -4,222,850 in 2025/Q4.", "EPS declined sharply to -2.02, showing weaker profitability.", "Technical trend remains bearish with SMA_200 > SMA_20 > SMA_5."]
In the latest reported quarter, 2025/Q4, Imunon posted revenue of 0, which was flat year over year, and a net loss of -4,222,850, though that loss improved slightly year over year. EPS fell to -2.02, down 44.51% YoY, showing continued earnings weakness. Gross margin was 0, which indicates the business is still not generating meaningful operating traction.
Analyst sentiment is cautiously positive but very limited. On 2026-04-17, Maxim initiated coverage with a Buy rating and a $10 price target, which is a strong upside target versus the current price. However, there is no broader analyst momentum shown, so Wall Street pros appear positive on potential but not strongly validated yet.
